Library · Heart, blood & kidney · Cardiovascular protection and anti-fibrotic therapy
B7-33
Relaxin B7-33, B7-33 peptide, Relaxin B-chain peptide
Synthetic single-chain peptide derived from H2 relaxin, engineered in 2016 for better stability while keeping relaxin’s cardiovascular benefits. Shows anti-fibrotic, vessel-protective effects in animal heart-failure and fibrosis models; still preclinical, no human trials yet.
Research score 75/100. Reference only, not a dose.
- Cardiovascular Health
- Blood Pressure Regulation
- Anti-inflammatory
- Cardioprotection
- US status
- Research Chemical
- Approval
- Research Chemical Only
- Evidence
- Optimized H2 relaxin analogue. Anti-fibrotic and vasoprotective effects without the hemodynamic side effects of native relaxin.
- Research score
- 75 / 100
- Indication
- Investigational - Cardiovascular Disease
- Origin
- Australia
- Source category
- Heart & Cardiovascular
- Status group
- Research chemical
Mechanism
Selectively activates RXFP1 receptors, raising cAMP/NO signaling and eNOS-driven nitric oxide for vasodilation, while suppressing TGF-β/Smad2 and MMP activity to limit cardiac fibrosis and inflammation.
Safety file
Appears promising; unlike native relaxin it doesn’t trigger the cAMP pathway linked to fast heart rate and tumor growth, with minimal adverse effects in animals.
- Potential blood pressure changes
- Injection site reactions
- Cardiovascular effects requiring monitoring